⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157480 | 0.83 | — | — | |
| SCHEMBL6980482 | 0.81 | NFKB1 (0.33) | — | |
| SCHEMBL15756046 | 0.77 | — | — | |
| SCHEMBL208485 | 0.73 | — | — | |
| SCHEMBL5579866 | 0.71 | — | — | |
| SCHEMBL3760336 | 0.69 | — | — | |
| SCHEMBL4157084 | 0.68 | — | — | |
| SCHEMBL10650634 | 0.67 | — | — | |
| SCHEMBL209331 | 0.67 | — | — | |
| SCHEMBL6983226 | 0.65 | CA12 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-3662913-A1 | NUCLEIC-ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Kirin Co., Ltd. (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-20180353434-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-2567951-B1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-3301086-A1 | PRODUCTION OF A COMPOSITION CONTAINING A COMPLEX BETWEEN A MEMBRANE COMPOSED OF A LIPID MONOLAYER AND A NUCLEIC ACID, AND, A LIPID MEMBRANE FOR ENCAPSULATING THE COMPLEX THEREIN | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9920028-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| US-9913907-B2 | RNAi pharmaceutical composition for suppressing expression of KRAS gene | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-03-13 | — | — | US | disclosed |
| EP-3275448-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9845306-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-19 | — | — | US | disclosed |
| US-9839616-B2 | Lipid nano particles comprising cationic lipid for drug delivery system | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| US-5973094-A | Functional polymers | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0794199-A2 | Novel functional polymers | WAKO PURE CHEMICAL INDUSTRIES, LTD (JP) | 1997-09-10 | — | — | EP | disclosed |